نتایج جستجو برای: tamoxifen citrate

تعداد نتایج: 25062  

Journal: :Cancer research 1986
C A Sawka K I Pritchard A H Paterson D J Sutherland D B Thomson W E Shelley R E Myers B G Mobbs A Malkin J W Meakin

Tamoxifen was evaluated as initial hormone therapy for metastatic breast cancer in 85 premenopausal patients. Tamoxifen responders continued on tamoxifen, while tamoxifen failures and initial responders who later progressed were to receive ovarian ablation next. Of 74 evaluable patients, 5 had complete responses (CR) and 15 had partial responses (PR) while 12 remained stable (ST), giving respon...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2000
J M Schafer E S Lee R M O'Regan K Yao V C Jordan

MCF-7 cells are used routinely to study tamoxifen-stimulated drug resistance in vivo. However, unlike MCF-7 cells, T47D cells express mutant p53 protein and lose the estrogen receptor (ER) during long-term estrogen deprivation in vitro [Pink et al., Br. J. Cancer, 74: 1227-1236, 1996 (erratum, Br. J. Cancer, 75: 1557, 1997)]. As a result, T47D tumors may respond differently from MCF-7 tumors to...

Journal: :Cancer research 2008
Anjali Naresh Ann D Thor Susan M Edgerton Kathleen C Torkko Rakesh Kumar Frank E Jones

Greater than 40% of breast cancer patients treated with tamoxifen exhibit de novo or acquired tumor resistance. Recent clinical evidence indicates that loss of expression of HER4 is an independent marker for tamoxifen resistance. In direct corroboration with clinical observations, suppression of HER4 expression in the tamoxifen-sensitive MCF-7 and T47D breast tumor cell lines resulted in resist...

Journal: :Molecular cancer research : MCR 2013
Akriti Kharbanda Hasan Rajabi Caining Jin Deepak Raina Donald Kufe

Tamoxifen resistance of estrogen receptor-positive (ER+) breast cancer cells has been linked in part to activation of receptor tyrosine kinases, such as HER2, and the PI3K-AKT pathway. Mucin 1 (MUC1) is aberrantly overexpressed in about 90% of human breast cancers, and the oncogenic MUC1-C subunit is associated with ERα. The present studies using HER2 overexpressing BT-474 breast cancer cells, ...

Journal: :Journal of the National Cancer Institute 1998
M W DeGregorio

BACKGROUND Tamoxifen has been shown to promote the growth of human endometrial tumors implanted in athymic mice, and it has been associated with a twofold to threefold increase in endometrial cancer. Toremifene, a chlorinated derivative of tamoxifen, and ICI 182,780, a pure antiestrogen, are two new antiestrogens being developed for the treatment of breast cancer. The effects of these drugs on ...

محمودی , محسن, مقدم نیا , علی اکبر, نیک بخش, نوین , هاشمی , سیدرضا,

Background and purpose: Gynecomastia -benign proliferation of male breast glandular tissue- occurs due to increased ratio of estrogen to androgen activity. Çonsidering the lack of studies on the effects of Tamoxifen on gynecomastia in Ïran, and also scarcity of such studies in other countries, this study was conducted to determine the effect of Tamoxifen in the treatment of gynecomastia. Mat...

2006
Emile F. Nuwaysir Yvonne P. Dragan Colin R. Jefcoate V. Craig Jordan Henry C. Pitot Robert H. Lurie

The nonsteroidal antiestrogen tamoxifen is widely used in breast cancer treatment and is currently under evaluation as a chemopreventive agent for individuals at high risk of contracting the disease. The effects of tamoxifen administration on the expression of xenobiotic metabolizing enzymes in F344 rat liver have been investigated. Tamoxifen administra tion for 7 days produced a dose-dependent...

Journal: :Journal of the National Cancer Institute 1997
B Fisher J Dignam N Wolmark A DeCillis B Emir D L Wickerham J Bryant N V Dimitrov N Abramson J N Atkins H Shibata L Deschenes R G Margolese

BACKGROUND The B-20 study of the National Surgical Adjuvant Breast and Bowel Project (NSABP) was conducted to determine whether chemotherapy plus tamoxifen would be of greater benefit than tamoxifen alone in the treatment of patients with axillary lymph node-negative, estrogen receptor-positive breast cancer. METHODS Eligible patients (n = 2306) were randomly assigned to one of three treatmen...

2013
Miguel A. Valverde

Tamoxifen is an antiestrogen frequently used in the treatment of breast cancer and is currently being assessed as a prophylactic for those at high risk of developing tumors. We have found that tamoxifen and its derivatives are highaffinity blockers of specific chloride channels. This blockade appears to be independent of the interaction of tamoxifen with the estrogen receptor and therefore refl...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید